Hangzhou Testsea biotechnology co., LTD. is a national high-tech enterprise, it located in Hangzhou. Testsea has lots of researcher and worker who graduated from Zhejiang university and overseas. Testsea is specialized in the research, development, production and sales of raw materials for medical diagnosis and food safety testing. we has applied for 28 kinds of patents which covering medical diagnosis, food safety rapid testing, food enzymatic immunoassay and new enzyme preparation. Testsea provides perfect raw material solutions for scientific research institutions, enterprises, research institutes and other institutions in global. Testsea total business area is more than 16000 square meters, including 8000 square meters of GMP 100,000-level purification workshop, our company is strictly following with ISO13485 and ISO9001 quality management system operation with research, production, quality control, finance, domestic sales and international sales etc. Our products are well accepted by many users in domestic and abroad. In addition, we establish a good business relationship with many domestic universities and in vitro diagnostic production enterprises, even with southeast Asia, Europe, Africa, Latin America and other countries.

Testsea has a research and development team led by doctors and masters with professinal workers and well-equipment facility. The production capacity of recombinant antigen has reached 18g/ month.

Testsea pursuit of "integrity, quality, responsibility" concept and adhere the quality, the purpose of serving the society and constantly develop new high-quality diagnostic materials effortly.
Rapid diagnostic test for fertility, infectious disease, drug of abuse and veterinary.

Rapid diagnostic tests (RDTs) are a type of point-of-care diagnostic, meaning that these assays are intended to provide diagnostic results conveniently and immediately to the patient while still at the health facility, screening site, or other health care provider. Receiving diagnosis at the point of care reduces the need for multiple visits to receive diagnostic results, thus improving specificity of diagnosis and the the chances the patient will receive treatment, reducing dependence on presumptive treatment, and reducing the risk that the patient will get sicker before a correct diagnosis is made. Rapid tests are used in a variety of point-of care-settings—from homes to primary care clinics or emergency rooms -- and many require little to no laboratory equipment or medical training.